<DOC>
	<DOCNO>NCT02530918</DOCNO>
	<brief_summary>The purpose study test DS-7080a , monoclonal antibody , new treatment neovascular age-related macular degeneration ( AMD ) . The hypothesis study DS-7080a safe show preliminary efficacy patient neovascular AMD either alone combination ranibizumab . This study organize 2 part : Part 1 Dose Escalation Part 2 Dose Expansion . In Part 1 , subject enrol 3 sequential , ascend dose-level cohort non-randomized uncontrolled manner . In Part 2 , subject randomize 1 3 arm either monotherapy DS-7080a monotherapy ranibizumab , active control , combination therapy DS-7080a plus ranibizumab ( ranibizumab administer 30 minute prior DS-7080a ) .</brief_summary>
	<brief_title>Study DS-7080a Treatment Neovascular Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>≥ 50 year age ; Active primary subfoveal choroid neovascularization ( CNV ) lesion secondary agerelated macular degeneration ( AMD ) ; CNV ≥ 50 % total lesion size study eye ; Central subfield thickness &gt; 315 µm spectral domain optical coherence tomography ( SDOCT ) study eye ; For Part 1 , ETDRS BCVA letter score ≤ 49 ( approximately 20/100 bad ) study eye ≥ 49 ( approximately 20/100 good ) fellow eye Screening Visit ; For Part 2 , ETDRS BCVA letter score 78 25 ( approximately 20/32 20/320 ) study eye . For Part 1 , ocular ( study eye ) systemic treatment surgery neovascular AMD within 4 week Baseline Visit , except dietary supplement vitamin ; For Part 2 , prior therapy study eye within 3 month Baseline Visit , except dietary supplement vitamin ; Use long act steroid , either systemically intraocularly , within 6 month Baseline Visit ; Total lesion size &gt; 12 disc area ( 30.5 mm2 ) study eye ; For Part 1 , subretinal hemorrhage ≥ 50 % total lesion area study eye ; For Part 1 , scar fibrosis , make &gt; 50 % total lesion involve center fovea study eye ; Presence retinal pigment epithelial tear rip involve macula study eye ; History vitreous hemorrhage within 4 week prior Screening Visit study eye ; The presence cause CNV AMD ; Prior vitrectomy study eye ; History retinal detachment treatment surgery retinal detachment study eye ; Any history full thickness macular hole study eye ; Any intraocular periocular surgery within 3 month Baseline Visit study eye , except lid surgery ; Uncontrolled glaucoma study eye ; Active intraocular inflammation periocular infection either eye ; Any history uveitis either eye scleromalacia either eye ; Aphakia pseudophakia study eye ; Previous therapeutic radiation region study eye ; History corneal transplant corneal dystrophy study eye ; Significant medium opacity study eye ( e.g . cataract ) could require either medical surgical intervention study period ; Women pregnant , breastfeeding , childbearing potential unwilling practice two measure adequate contraception throughout study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neovascular Age-Related Macular Degeneration</keyword>
	<keyword>DS-7080a Monoclonal Antibody</keyword>
</DOC>